Novel Drugs for Diabetes Therapy
Author:
Publisher
Springer International Publishing
Link
https://link.springer.com/content/pdf/10.1007/164_2021_574
Reference84 articles.
1. Abdelmalek MF, Choi J, Kim Y, Seo K, Hompesch M (2020) HM15211, a novel GLP-1/GIP/glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: a phase 1b/2a, multi-center, randomized, placebo-controlled trial. J Hepatol 73(Suppl. 1):S124
2. Abramson A, Caffarel-Salvador E, Khang M, Dellal D, Silverstein D, Gao Y et al (2019) An ingestible self-orienting system for oral delivery of macromolecules. Science 363(6427):611–615
3. Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L et al (2018) MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet 391(10140):2607–2618
4. Baggio LL, Drucker DJ (2021) Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab 46:101090
5. Bailey CJ, Day C (2018) Treatment of type 2 diabetes: future approaches. Br Med Bull 126(1):123–137
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Association between dipeptidyl peptidase-4 inhibitor use and diabetic retinopathy: a systematic review and meta-analysis of real-world studies;BMC Ophthalmology;2024-06-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3